SEC Comment Letter 0000000000-25-008820 to atai Life Sciences Luxembourg S.A. (CIK 0002081043)

atai Life Sciences Luxembourg S.A. (CIK 0002081043)
Date: Aug. 19, 2025 · CIK: 0002081043 · Accession: 0000000000-25-008820

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

August 19, 2025

Author

Division of

Form

UPLOAD

Company

atai Life Sciences Luxembourg S.A. (CIK 0002081043)

Letter

Re: atai Life Sciences Luxembourg S.A. Draft Registration Statement on Form S-4 Submitted August 13, 2025 CIK No. 0002081043 Dear Srinivas Rao:

August 19, 2025

Srinivas Rao Chief Executive Officer atai Life Sciences Luxembourg S.A. Prof. J.H. Bavincklaan 7 1183 AT Amstelveen The Netherlands

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Brian Robert Umanoff, Esq.

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 19, 2025

Srinivas Rao
Chief Executive Officer
atai Life Sciences Luxembourg S.A.
Prof. J.H. Bavincklaan 7
1183 AT Amstelveen
The Netherlands

 Re: atai Life Sciences Luxembourg S.A.
 Draft Registration Statement on Form S-4
 Submitted August 13, 2025
 CIK No. 0002081043
Dear Srinivas Rao:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tyler Howes at 202-551-3370 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Brian Robert Umanoff, Esq.
</TEXT>
</DOCUMENT>

SecProbe.io